Forbes

Twenty minutes lost to a balky booking system, and the staff already knew. Two questions every leader should ask to find the friction in patient and customer experience.

The U.S. is on the verge of losing its measles elimination status for the first time in 25 years. Oubreaks are a hidden tax, leading to higher costs and economic losses.

In this week’s edition of InnovationRx, we look at Fortell’s efforts to make a better hearing aid, Abby Care’s business getting payment for caregivers, J&J’s $5.5 billion talc settlement, Scribe Therapeutics’ IPO, and more.

A profitable rural Maine hospital plans to close labor & delivery, furthering a wave of state-wide maternity closures. What this means for women and communities.

Humana reported second quarter net income of $694 million as costs of care for older adults in its Medicare Advantage plans fell in line with company expectations.

As the reliance on technology increases, healthcare leaders need to invest heavily in cyber-protection measures.

A study from Down Under did look at who had more recorded farts per day, men or women. It also showed when the peak amount of flatulence seemed to occur.

A targeted antibody‑drug conjugate wipes out measurable residual disease in adult acute lymphoblastic leukemia, cutting relapse risk and extending long‑term survival.

Advocates for Medicare for All should abandon reference to a dated safety net program whose flaws are becoming more pronounced by the day.

The U.S. FDA now lists 12 different ongoing food-borne illness outbreaks including Cyclospora and Salmonella ones with the sources of eight still “Not Yet Identified."

Health insurer Centene’s net income eclipsed $1 billion in the second quarter as the company is getting a better handle on rising costs of people in its health plans.

Many legacy hardware and software players are increasingly seeing value in entering the healthcare arena.

If Sec. Kennedy and his inner circle are serious about removing toxins that can threaten health, they should look at our nation’s generic drug supply,